Compare · AVTR vs HBIO
AVTR vs HBIO
Side-by-side comparison of Avantor Inc. (AVTR) and Harvard Bioscience Inc. (HBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and HBIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.71B, about 288.2x HBIO ($26.7M).
- Over the past year, AVTR is down 11.9% and HBIO is up 65.7% - HBIO leads by 77.7 points.
- AVTR has hit the wire 4 times in the past 4 weeks while HBIO has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 2 for HBIO).
- Company
- Avantor Inc.
- Harvard Bioscience Inc.
- Price
- $11.29+6.86%
- $6.60+3.77%
- Market cap
- $7.71B
- $26.7M
- 1M return
- +16.87%
- -0.68%
- 1Y return
- -11.93%
- +65.75%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2000
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 2
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Harvard Bioscience Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
Latest AVTR
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Murthy Mala was granted 25,270 shares, increasing direct ownership by 57% to 69,479 units (SEC Form 4)
Latest HBIO
- Director Eade Katherine A. was granted 16,556 shares, increasing direct ownership by 39% to 58,669 units (SEC Form 4)
- Director Snider William was granted 16,556 shares, increasing direct ownership by 52% to 48,556 units (SEC Form 4)
- Director Denelsky Stephen J was granted 16,556 shares, increasing direct ownership by 79% to 37,556 units (SEC Form 4)
- Director Gagnon Robert E. was granted 16,556 shares, increasing direct ownership by 151% to 27,556 units (SEC Form 4)
- Director Benson Seth Benjamin was granted 16,556 shares, increasing direct ownership by 151% to 27,556 units (SEC Form 4)
- SEC Form S-8 filed by Harvard Bioscience Inc.
- Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Harvard Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Harvard Bioscience Inc.
- SEC Form 10-Q filed by Harvard Bioscience Inc.